Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) traded down 5.8% during trading on Wednesday . The company traded as low as $17.00 and last traded at $17.10. 40,717 shares traded hands during trading, a decline of 89% from the average session volume of 354,448 shares. The stock had previously closed at $18.15.
Analyst Upgrades and Downgrades
A number of equities research analysts have issued reports on the company. HC Wainwright started coverage on Bicara Therapeutics in a research report on Friday, December 6th. They set a "buy" rating and a $42.00 target price for the company. Stifel Nicolaus assumed coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They issued a "buy" rating and a $47.00 target price on the stock. Cantor Fitzgerald assumed coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They set an "overweight" rating for the company. RODMAN&RENSHAW upgraded Bicara Therapeutics to a "strong-buy" rating in a report on Tuesday, November 5th. Finally, Morgan Stanley began coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They issued an "overweight" rating and a $35.00 price objective on the stock. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Bicara Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $43.00.
Get Our Latest Analysis on BCAX
Bicara Therapeutics Price Performance
The firm's 50 day simple moving average is $20.98.
Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($1.60) EPS for the quarter, missing analysts' consensus estimates of ($0.46) by ($1.14). Equities research analysts forecast that Bicara Therapeutics Inc. will post -2.59 EPS for the current fiscal year.
Institutional Trading of Bicara Therapeutics
Several institutional investors have recently bought and sold shares of BCAX. RA Capital Management L.P. acquired a new position in shares of Bicara Therapeutics in the 3rd quarter worth approximately $177,169,000. FMR LLC acquired a new stake in Bicara Therapeutics in the third quarter worth about $57,913,000. Braidwell LP bought a new stake in Bicara Therapeutics during the 3rd quarter worth about $42,219,000. Janus Henderson Group PLC bought a new position in shares of Bicara Therapeutics in the 3rd quarter valued at about $30,329,000. Finally, Baker BROS. Advisors LP bought a new stake in shares of Bicara Therapeutics during the third quarter worth approximately $21,225,000.
About Bicara Therapeutics
(
Get Free Report)
Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
See Also
Before you consider Bicara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicara Therapeutics wasn't on the list.
While Bicara Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
